Home > Back to Publisher > Report Information

Personalized Medicine: Technologies and the Global Market

BCC Research
July 1, 2009
190 Pages - SKU: WA2305212

Abstract Table of Contents Related Reports

Countries covered: Global

This Report:

Provides an in-depth look at the global market for personalized medicine
Measures the diagnostic market segment for personalized medicine, focusing on its high growth rate
Offers current market data and forecasts through 2014 for the worldwide market for personalized medicine
Estimates the growth of all submarkets for personalized medicine in terms of technology, products, services, geography and applications areas
Analyzes the current personalized medicine business model and looks at industry structure, offering company profiles and patent analysis
Discusses market opportunities for various stakeholders.

CHAPTER ONE: INTRODUCTION: STUDY GOALS AND OBJECTIVES; REASONS FOR DOING THE STUDY; SCOPE OF REPORT; INTENDED AUDIENCE; INFORMATION SOURCES AND METHODOLOGY; ANALYST CREDENTIALS; RELATED BCC REPORTS; BCC ONLINE SERVICES; DISCLAIMER
CHAPTER TWO: SUMMARY
CHAPTER THREE: MARKET OVERVIEW: CHANGING TRENDS: FROM BLOCKBUSTER MODEL TO PERSONALIZED MODEL; MAJOR MARKET DRIVERS; ACCURACY AND PREVENTIVE DIAGNOSIS; COST-EFFECTIVE IN LONG RUN; RECUPERATIVE BENEFITS; MORE EFFECTIVE THAN CONVENTIONAL TREATMENTS; MARKET RESTRAINTS; RELUCTANCE AMONG PHARMACEUTICAL COMPANIES; LEGAL ISSUES DUE TO INTELLECTUAL PROPERTY RIGHTS; LACK OF INSURANCE COVERAGE; STAKEHOLDERS’ OPPORTUNITIES; DEFINING THE OVERALL PERSONALIZED MEDICINE MARKET; DEFINING THE PERSONALIZED MEDICINE TECHNOLOGY MARKET; DEFINING THE PERSONALIZED MEDICINE PRODUCTS AND SERVICES MARKET; DEFINING THE PERSONALIZED MEDICINE APPLICATIONS MARKET; DEFINING THE PERSONALIZED MEDICINE MARKET BY GEOGRAPHY; PATENT ANALYSIS
CHAPTER FOUR: GLOBAL PERSONALIZED MEDICINE MARKET BY TECHNOLOGY: ANALYSIS OF PATENTS BY TECHNOLOGY; GLOBAL PHARMACOGENOMICS MARKET IN PERSONALIZED MEDICINE; MARKET DRIVERS; Increased Health Awareness and Preventive Diagnosis to Boost the Demand for Pharmacogenomics; Increased Revenue Opportunities for Diagnostic and Drug Companies; Enhanced Treatment and Better Drug Efficacy Rate; MARKET RESTRAINTS; Intellectual Property Rights Problem; Legal Issues within Nations; PHARMACOGENOMIC SERVICES MARKET; Global Market for SNP Genotyping; Cost Effective Sequencing Boosts Demand; Oligopoly Market Restrains Entry of New; Companies; Global Market for SNP Genotyping Services; Global Market for SNP Genotyping Products; Major Companies and Products; Global Market for Pharmacogenomic Drug Discovery and Delivery; Market for SSR-Based Diagnosis; Market for VNTRs-Based Diagnosis; Global Market for Pharmacogenomic Therapy; Global Market for Other Pharmacogenomic Services; TOP COMPANIES; PHARMACOGENOMIC PRODUCTS MARKET; Markets for Pharmacogenomic Drugs; Markets for Equipment in Pharmacogenomics; MAJOR TECHNIQUES; GLOBAL PHARMACOPROTEOMICS MARKET IN PERSONALIZED MEDICINE; MARKET DRIVERS; Superior Diagnostic Results with Protein Studies; High Revenue Generation Attracts More Market Players; MARKET RESTRAINTS; Continuous Change in Protein Formation Makes it a Costly Treatment; TOP COMPANIES; MARKET FOR PHARMACOPROTEOMICS SERVICES; PHARMACOPROTEOMIC PRODUCTS; MAJOR TECHNOLOGIES; GLOBAL STEM CELL THERAPY MARKET IN PERSONALIZED MEDICINE; MARKET DRIVERS; Highly Untapped Market; Multiple Treatments with One Stem Cell; Government Appreciation in the U.S. for Embryonic Stem Cell Research; MARKET RESTRAINTS; Time Consuming Treatment; Side Effects; TOP COMPANIES; ADULT STEM CELL THERAPY; Market Drivers; Enhanced Treatment for Spinal Cord Injury and Diseases such as Cancer; Federal Funding in the U.S. for Adult Stem Cell Therapy; Market Restraints; Stem Cell Therapy Requires Frequent Treatment; EMBRYONIC STEM CELL THERAPY; Market Drivers; Enhanced Curative Potential Will Attract More Customers; Sufficient Knowledge on many Ranges of Stem Cells; Market Restraints; Religious and Political Issues; OTHER TECHNIQUES; GLOBAL POINT OF CARE MARKET IN PERSONALIZED MEDICINE; MARKET DRIVERS; Fast, Easy, and Exact Personalized Care; Developed Technology Paves the Way for a Developed Market; MARKET RESTRAINTS; Time-Consuming Realization of Insurance Policies; TOP COMPANIES AND THEIR PRODUCTS; GLOBAL METABOLOMICS MARKET IN PERSONALIZED MEDICINE; MARKET DRIVERS; Enhanced R&D in Drug Discovery Process; Competitive Advantage and Less Regulatory Hurdles in Final Drug Delivery; MARKET RESTRAINTS; Adopted by Fewer Companies; TOP COMPANIES; GLOBAL PHARMACOGENETICS MARKET IN PERSONALIZED MEDICINE; MARKET DRIVERS; Preventive and Curative Treatments Use Pharmacogenetic Technique; Enhanced Drugs for Diseases such as Cancer/Cardiovascular Problems; MARKET RESTRAINTS; High Cost; TOP COMPANIES; GLOBAL PHARMACOKINETICS MARKET IN PERSONALIZED MEDICINE; MARKET DRIVERS; Better Evaluation of the Body’s Response to the Drug; Quantitative Results Make it User Friendly for Patients; Untapped Market Means Potential Growth for Companies; MARKET RESTRAINTS; Assumptions of Mathematical Models Can Give Unwanted Results; Costly Treatment Hampers Market Growth; TOP COMPANIES; GLOBAL PHARMACODYNAMICS MARKET IN PERSONALIZED MEDICINE
CHAPTER FIVE: GLOBAL MARKET FOR PERSONALIZED MEDICINE BY SERVICES: GLOBAL MARKET FOR DRUG DEVELOPMENT/DRUG DELIVERY SERVICE; MARKET DRIVERS; Shift of Trend from Blockbuster Drugs to Tailored Drugs; Higher Efficacy of Drugs with Personalized Medicine; MARKET RESTRAINTS; Expensive Drugs In Comparison To Blockbuster Drugs; TOP COMPANIES; GLOBAL MARKET FOR DIAGNOSIS; PHARMACOGENOMICS BASED DIAGNOSIS; Market Drivers; Individual Gene Tests are Increasing Revenues for Diagnostic Players; Market Restraints; Rapidly Evolving Technology is Not Aligned to Fixed Regulatory System; PHARMACOPROTEOMICS BASED DIAGNOSIS; Market Drivers; In-Depth Research Provides a Lot of Information for Diagnosis; Market Restraints; Costly Treatment Due to Requirement of Continuous Monitoring of Changing Protein Formation; PHARMACOGENETICS BASED DIAGNOSIS; GLOBAL MARKET FOR MONITORING AND THERAPY SERVICES; MONITORING SERVICES; THERAPEAUTIC SERVICES; GLOBAL MARKET FOR OTHER SERVICES
CHAPTER SIX: GLOBAL MARKET FOR PERSONALIZED MEDICINE BY PRODUCTS: GLOBAL PERSONALIZED MEDICINE MARKET FOR DIAGNOSTICS EQUIPMENT; MARKET DRIVERS; Increased Demand for Genetic and Proteomic Tests; MARKET RESTRAINTS; Fast Changing Technology; MARKET DRIVERS; Improved Technology Along with Low-Cost Monitoring and Therapeutic Devices; GLOBAL PERSONALIZED MEDICINE MARKET FOR BIOINFORMATICS PRODUCTS; MARKET DRIVERS; Bioinformatics Reduces Cost of Drug Development; MARKET RESTRAINTS; High Initial Investment Hinders Small and Medium Sized Companies; GLOBAL PERSONALIZED MEDICINE MARKET FOR DRUGS; DRUG STAGES; GLEEVEC; Market Drivers; Higher Efficacy of Gleevec Gives it a Large Consumer Base; Gleevec as a Pill Makes it Easy to Consume; Assistance for Reimbursement from Insurance Companies; Market Restraints; High Drug Cost is Affecting Market Growth; Inherent Side Effects of Gleevec; HERCEPTIN; Market Drivers; Enhanced Treatment with Reduced Risk of Reoccurrence of Breast Cancer; Market Restraints; Tailor Made Herceptin Still Carries Inherent Side Effects; ZIAGEN; Market Drivers; Customizable for Children; Market Restraints; Treatment with Ziagen Cannot Be Restarted; IRESSA AND TARCEVA; Iressa; Market Drivers; • Iressa in Pills Makes it User Friendly; Market Restraints; • FDA Ban on Iressa Is Keeping it Away from the U.S. Market; Tarceva; ERBITUX; Market Drivers; Multiple Cancers Are Treated with Erbitux, which Gives it a Large Patient Base; Enhanced Survival Results when Radiotherapy Is Combined with Erbitux; OTHERS
CHAPTER SEVEN: GLOBAL MARKET FOR PERSONALIZED MEDICINE BY APPLICATIONS: PERSONALIZED MEDICINE MARKET FOR CARDIOVASCULAR DISEASE; MARKET DRIVERS; Possible Preventive Measure; MARKET RESTRAINTS; Lack of Proactive Approach for Early Diagnosis; PERSONALIZED MEDICINE MARKET FOR BREAST CANCER; MARKET DRIVERS; Fewer Side Effects with Personalized Medicine; MARKET RESTRAINTS; Resistance to Adopting New Methods of Treatment; RECENT DEVELOPMENTS; PERSONALIZED MEDICINE MARKET FOR LEUKEMIA; MARKET DRIVERS; Huge Market Potential for Leukemia; MARKET RESTRAINTS; Lack of Awareness that Surgery Is the Only Way to Treat Leukemia; PERSONALIZED MEDICINE MARKET FOR LUNG CANCER; MARKET DRIVERS; Higher Efficiency Than Conventional Lung Cancer Treatment; Availability of Drugs in the Form of Pills Makes Treatment User Friendly; MARKET RESTRAINTS; Lack of FDA Approval for Certain Personalized Drugs; RECENT DEVELOPMENTS; PERSONALIZED MEDICINE MARKET FOR TREATING HIV/AIDS; MARKET DRIVERS; Personalized Medicine Improves Life Expectancy of a Patient; Easy Reimbursement for Aids Patients from NGOs/Government Organizations; MARKET RESTRAINTS; Lack of Awareness Among Patients; PERSONALIZED MEDICINE MARKET FOR NEUROLOGICAL DISORDERS; MARKET DRIVERS; Enhanced Treatment; MARKET RESTRAINTS; Apprehensive to Try Out New Medications; PERSONALIZED MEDICINE MARKET FOR DIABETES; MARKET DRIVERS; Early Diagnosis Can Help Prevent Diabetes; MARKET RESTRAINTS; Casual Approach towards Diabetes; RECENT DEVELOPMENTS; PERSONALIZED MEDICINE MARKET FOR ASTHMA; MARKET DRIVERS; Every Asthma Case Is Distinct, Needs Custom-Tailored Treatment; Asthma Treatment Needs Regular Monitoring; OTHER APPLICATIONS
CHAPTER EIGHT: GLOBAL PERSONALIZED MARKET BY GEOGRAPHY: ANALYSIS OF PATENTS BY GEOGRAPHY; PERSONALIZED MEDICINE MARKET IN NORTH AMERICA; GOVERNMENTAL SUPPORT; DEMOGRAPHIC STATUS; RECESSION; NORTH AMERICAN MARKET FOR PERSONALIZED MEDICINE TECHNOLOGIES; NORTH AMERICAN MARKET FOR PERSONALIZED MEDICINE SERVICES; NORTH AMERICAN MARKET FOR PERSONALIZED MEDICINE PRODUCTS; NORTH AMERICAN MARKET FOR APPLICATIONS OF PERSONALIZED MEDICINE; RECENT DEVELOPMENTS; PERSONALIZED MEDICINE MARKET IN EUROPE; EUROPEAN UNION IS FUELING THE GROWTH OF PERSONALIZED MEDICINE IN EUROPE; HIGH PER CAPITA EXPENDITURE ON HEALTHCARE; EUROPEAN MARKET FOR PERSONALIZED MEDICINE TECHNOLOGIES; EUROPEAN MARKET FOR PERSONALIZED MEDICINE SERVICES; EUROPEAN MARKET FOR PERSONALIZED MEDICINE PRODUCTS; EUROPEAN MARKET FOR APPLICATIONS OF PERSONALIZED MEDICINE; RECENT DEVELOPMENTS; PERSONALIZED MEDICINE MARKET IN ASIA PACIFIC; MOST DENSELY POPULATED REGION WITH FAST DEVELOPING COUNTRIES LIKE CHINA AND INDIA; A LARGE NUMBER OF PATIENTS WITH UNMET MEDICAL REQUIREMENTS IN THIS REGION; LOW PER CAPITA EXPENDITURE ON HEALTHCARE IN COMPARISON TO OTHER REGIONS; ASIA PACIFIC MARKET FOR PERSONALIZED MEDICINE TECHNOLOGIES; ASIA PACIFIC MARKET FOR PERSONALIZED MEDICINE BY PRODUCTS AND SERVICES; ASIA PACIFIC MARKET FOR APPLICATIONS OF PERSONALIZED MEDICINE; RECENT DEVELOPMENTS; PERSONALIZED MEDICINE MARKET IN THE REST OF WORLD (ROW); UNAFFECTED BY RECESSION, THE MIDDLE EAST IS BOOSTING THE GROWTH; LARGE NUMBER OF AIDS PATIENT IN AFRICAN COUNTRIES; POLITICAL AND ECONOMIC INSTABILITY IN MOST OF THE COUNTRIES
CHAPTER NINE: COMPANY PROFILES: ABBOTT; OVERVIEW; STRATEGY; AFFYMETRIX; OVERVIEW; STRATEGY; AGENDIA BV; OVERVIEW; STRATEGY; ASURAGEN; OVERVIEW; STRATEGY; BAYER HEALTHCARE; STRATEGY; BIOGEN (IDEC); OVERVIEW; STRATEGY; BRISTOL-MYERS SQUIBB; OVERVIEW; STRATEGY; CELERA DIAGNOSTICS; OVERVIEW; STRATEGY; CEPHEID; OVERVIEW; STRATEGY; CLINICAL DATA; OVERVIEW; STRATEGY; CURAGEN CORP.; OVERVIEW; STRATEGY; DAKO DENMARK A/S; OVERVIEW; STRATEGY; DECODE GENETICS; OVERVIEW; STRATEGY; DNA DIRECT, INC; OVERVIEW; STRATEGY; DXS LTD.; OVERVIEW; STRATEGY; EXACT SCIENCES CORP.; OVERVIEW; STRATEGY; EXAGEN DIAGNOSTICS; OVERVIEW; GENE LOGIC (AN OCIMUM BIOSOLUTIONS COMPANY); OVERVIEW; STRATEGY; GENELEX CORP; OVERVIEW; STRATEGY; GENENTECH, INC.; OVERVIEW; STRATEGY; GENOMIC HEALTH, INC.; OVERVIEW; STRATEGY; GEN-PROBE; OVERVIEW; STRATEGY; GENTA; OVERVIEW; STRATEGY; GLAXOSMITHKLINE; OVERVIEW; STRATEGY; ILLUMINA; OVERVIEW; STRATEGY; LUMINEX CORP; OVERVIEW; MILLENNIUM; OVERVIEW; STRATEGY; MONOGRAM BIOSCIENCES; OVERVIEW; STRATEGY; MYRIAD GENETICS, INC; OVERVIEW; STRATEGY; NANOGEN; OVERVIEW; STRATEGY; NOVARTIS; OVERVIEW; STRATEGY; OSMETECH PLC; OVERVIEW; STRATEGY; PROMEGA; OVERVIEW; STRATEGY; QIAGEN; OVERVIEW; STRATEGY; ROCHE DIAGNOSTICS; OVERVIEW; STRATEGY; SIEMENS HEALTHCARE DIAGNOSTICS; OVERVIEW; STRATEGY; TARGET DISCOVERY, INC.; OVERVIEW; STRATEGY; VENTANA MEDICAL SYSTEMS, INC; OVERVIEW; STRATEGY; WYETH; OVERVIEW; STRATEGY; APPENDIX; PATENTS ISSUED IN U.S.; PATENTS ISSUED IN EUROPE; PATENTS ISSUED IN JAPAN
LIST OF TABLES: SUMMARY TABLE GLOBAL MARKET FORECAST FOR PERSONALIZED; MEDICINE, BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS); TABLE 1 GLOBAL MARKET FOR STAKEHOLDERS, THROUGH 2014; ($ MILLIONS); TABLE 2 GLOBAL PERSONALIZED MEDICINE MARKET BY; PRODUCTS AND SERVICES, THROUGH 2014 ($ MILLIONS); TABLE 3 GLOBAL MARKET FORECAST FOR PERSONALIZED; MEDICINE, BY APPLICATION, THROUGH 2014 ($ MILLIONS); TABLE 4 GLOBAL PHARMACOGENOMICS MARKET IN; PERSONALIZED MEDICINE BY PRODUCTS AND SERVICES,; THROUGH 2014 ($ MILLIONS); TABLE 5 GLOBAL PHARMACOGENOMICS MARKET IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 6 GLOBAL PHARMACOGENOMICS MARKET IN; PERSONALIZED MEDICINE BY SERVICES, THROUGH 2014; ($ MILLIONS); TABLE 7 GLOBAL PHARMACOGENOMICS SERVICES MARKET IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 8 GLOBAL SNP GENOTYPING MARKET IN PERSONALIZED; MEDICINE BY DIAGNOSIS METHODS, THROUGH 2014; ($ MILLIONS); TABLE 9 GLOBAL SNP GENOTYPING MARKET IN PERSONALIZED; MEDICINE BY SERVICES, THROUGH 2014 ($ MILLIONS); TABLE 10 GLOBAL SNP GENOTYPING MARKET IN PERSONALIZED; MEDICINE BY PRODUCTS, THROUGH 2014 ($ MILLIONS); TABLE 11 MAJOR PRODUCTS IN SNP GENOTYPING; TABLE 12 GLOBAL DRUG DISCOVERY AND DELIVERY MARKET IN; PHARMACOGENOMICS, THROUGH 2014 ($ MILLIONS); TABLE 13 GLOBAL SSR BASED DIAGNOSIS MARKET IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 14 GLOBAL VNTR BASED DIAGNOSIS MARKET IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 15 GLOBAL PHARMACOGENOMIC THERAPY MARKET IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 16 MAJOR COMPANIES AND RESPECTIVE PRODUCTS IN; PHARMACOGENOMIC SERVICES; TABLE 17 GLOBAL PHARMACOGENOMICS MARKET IN; PERSONALIZED MEDICINE BY PRODUCTS, THROUGH 2014; ($ MILLIONS); TABLE 18 GLOBAL PHARMACOGENOMICS PRODUCTS MARKET IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 19 GLOBAL PHARMACOGENOMICS DRUGS MARKET IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 20 GLOBAL PHARMACOGENOMICS EQUIPMENT MARKET IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 21 GLOBAL MARKET FOR MAJOR PHARMACOGENOMIC; TECHNIQUES IN PERSONALIZED MEDICINE, THROUGH 2014; ($ MILLIONS); TABLE 22 GLOBAL PHARAMCOPROTEOMICS MARKET IN; PERSONALIZED MEDICINE BY PRODUCTS AND SERVICES,; THROUGH 2014 ($ MILLIONS); TABLE 23 GLOBAL PHARAMCOPROTEOMICS MARKET IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 24 MAJOR PRODUCTS IN PHARMACOPROTEOMICS; TABLE 25 GLOBAL PHARAMCOPROTEOMICS MARKET IN; PERSONALIZED MEDICINE BY SERVICES, THROUGH 2014; ($ MILLIONS); TABLE 26 GLOBAL PHARAMCOPROTEOMICS SERVICES MARKET IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 27 GLOBAL PHARAMCOPROTEOMICS MARKET IN; PERSONALIZED MEDICINE BY PRODUCTS, THROUGH 2014; ($ MILLIONS); TABLE 28 GLOBAL PHARAMCOPROTEOMICS PRODUCTS MARKET IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 29 GLOBAL PHARAMCOPROTEOMICS DRUGS MARKET IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 30 GLOBAL PHARAMCOPROTEOMICS MARKET IN; PERSONALIZED MEDICINE BY MAJOR TECHNOLOGY, THROUGH; 2014 ($ MILLIONS); TABLE 31 GLOBAL STEM CELL THERAPY MARKET IN; PERSONALIZED MEDICINE BY TECHNOLOGY, THROUGH 2014; ($ MILLIONS); TABLE 32 GLOBAL STEM CELL THERAPY MARKET IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 33 MAIN COMPANIES AND PRODUCTS IN STEM CELL; THERAPY; TABLE 34 RECENT PRODUCTS IN STEM CELL THERAPY; TABLE 35 GLOBAL ADULT STEM CELL THERAPY MARKET IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 36 GLOBAL POINT OF CARE MARKET IN PERSONALIZED; MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 37 TOP COMPANIES AND THEIR PRODUCTS IN; POINT OF CARE; TABLE 38 NEW TECHNOLOGIES IN POINT OF CARE; TABLE 39 GLOBAL METABOLOMICS MARKET IN PERSONALIZED; MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 40 MAJOR COMPANIES AND THEIR PRODUCTS; TABLE 41 GLOBAL PHARMACOGENETICS MARKET IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 42 MAIN PRODUCTS IN PHARMACOGENETICS; TABLE 43 GLOBAL PHARMACOKINETICS MARKET IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 44 MAIN PRODUCTS IN PHARMACOKINETICS; TABLE 45 GLOBAL PHARMACODYNAMICS MARKET IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 46 GLOBAL PERSONALIZED MEDICINE MARKET BY; SERVICES, THROUGH 2014 ($ MILLIONS); TABLE 47 GLOBAL PERSONALIZED MEDICINE SERVICES MARKET,; THROUGH 2014 ($ MILLIONS); TABLE 48 GLOBAL DRUG DEVELOPMENT AND DELIVERY MARKET; IN PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 49 GLOBAL PERSONALIZED MEDICINE DIAGNOSTIC; SERVICES MARKET, BY TECHNOLOGY, THROUGH 2014; ($ MILLIONS); TABLE 50 GLOBAL PERSONALIZED MEDICINE DIAGNOSTIC; SERVICES MARKET, THROUGH 2014 ($ MILLIONS); TABLE 51 GLOBAL PHARMACOGENOMIC DIAGNOSTIC SERVICES; MARKET, THROUGH 2014 ($ MILLIONS); TABLE 52 GLOBAL PHARMACOPROTEOMIC DIAGNOSTIC SERVICES; MARKET, THROUGH 2014 ($ MILLIONS); TABLE 53 GLOBAL PHARMACOGENETIC DIAGNOSTIC SERVICES; MARKET, THROUGH 2014 ($ MILLIONS); TABLE 54 GLOBAL PERSONALIZED MEDICINE MONITORING; SERVICES MARKET, THROUGH 2014 ($ MILLIONS); TABLE 55 GLOBAL PERSONALIZED MEDICINE THERAPEUTIC; SERVICES MARKET, THROUGH 2014 ($ MILLIONS); TABLE 56 GLOBAL OTHER SERVICES MARKET IN PERSONALIZED; MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 57 GLOBAL PERSONALIZED MEDICINE MARKET BY; PRODUCTS, THROUGH 2014 ($ MILLIONS); TABLE 58 GLOBAL PERSONALIZED MEDICINE PRODUCTS MARKET,; THROUGH 2014 ($ MILLIONS); TABLE 59 GLOBAL MARKET FOR DIAGNOSTIC EQUIPMENT IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 60 GLOBAL MARKET FOR MONITORING AND THERAPEUTIC; EQUIPMENT IN PERSONALIZED MEDICINE, THROUGH 2014; ($ MILLIONS); TABLE 61 GLOBAL MARKET FOR BIOINFORMATICS IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 62 GLOBAL MARKET FORECAST FOR DRUGS IN; PERSONALIZED MEDICINE BY PRODUCTS, THROUGH 2014; ($ MILLIONS); TABLE 63 GLOBAL MARKET FORECAST FOR DRUGS IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 64 GLOBAL MARKET FORECAST FOR GLEEVAC IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 65 GLOBAL MARKET FORECAST FOR HERCEPTIN IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 66 GLOBAL MARKET FORECAST FOR ZIAGEN IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 67 GLOBAL MARKET FORECAST FOR IRESSA & TARCEVA IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 68 GLOBOL MARKET FORECAST FOR ERBITUX IN; PERSONALIZED MEDICINE THROUGH 2014 ($ MILLIONS); TABLE 69 GLOBAL MARKET FORECAST FOR OTHER DRUGS IN; PERSONALIZED MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 70 GLOBAL MARKET FORECAST FOR TREATMENT OF; CARDIOVASCULAR DISEASES, THROUGH 2014 ($ MILLIONS); TABLE 71 GLOBAL MARKET FORECAST FOR BREAST CANCER; TREATMENT THROUGH 2014 ($ MILLIONS); TABLE 72 RECENT DEVELOPMENTS IN TREATMENT OF BREAST; CANCER; TABLE 73 GLOBAL MARKET FORECAST FOR LEUKEMIA TRETAMENT; THROUGH 2014 ($ MILLIONS); TABLE 74 GLOBAL MARKET FORECAST FOR LUNG CANCER; TREATMENT, THROUGH 2014 ($ MILLIONS); TABLE 75 GLOBAL MARKET FORECAST FOR AIDS TREATMENT; THROUGH 2014 ($ MILLIONS); TABLE 76 GLOBAL MARKET FORECAST FOR TREATING; NEUROLOGICAL DISORDERS, THROUGH 2014 ($ MILLIONS); TABLE 77 GLOBAL MARKET FORECAST FOR TREATMENT OF; DIABETES, THROUGH 2014 ($ MILLIONS); TABLE 78 RECENT DEVELOPMENTS IN TREATING DIABETES; TABLE 79 GLOBAL MARKET FORECAST FOR TREATING ASTHMA,; THROUGH 2014 ($ MILLIONS); TABLE 80 GLOBAL MARKET FORECAST FOR TREATING OTHER; CANCER/TUMOR, THROUGH 2014 ($ MILLIONS); TABLE 81 GLOBAL MARKET FORECAST FOR TREATING OTHER; DISEASES, THROUGH 2014 ($ MILLIONS); TABLE 82 GLOBAL MARKET FORECAST FOR PERSONALIZED; MEDICINE, THROUGH 2014 ($ MILLIONS); TABLE 83 NORTH AMERICAN MARKET FORECAST FOR; PERSONALIZED MEDICINE, BY TECHNOLOGY, THROUGH 2014; ($ MILLIONS); TABLE 84 NORTH AMERICAN MARKET FORECAST FOR; PERSONALIZED MEDICINE, BY SERVICES, THROUGH 2014; ($ MILLIONS); TABLE 85 NORTH AMERICAN MARKET FORECAST FOR; PERSONALIZED MEDICINE, BY PRODUCTS, THROUGH 2014; ($ MILLIONS); TABLE 86 NORTH AMERICAN MARKET FORECAST FOR; PERSONALIZED MEDICINE, BY APPLICATIONS, THROUGH 2014; ($ MILLIONS); TABLE 87 RECENT MERGERS AND ACQUISITIONS IN THE NORTH; AMERICAN MARKET; TABLE 88 EUROPEAN MARKET FORECAST FOR PERSONALIZED; MEDICINE, BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS); TABLE 89 EUROPEAN MARKET FORECAST FOR PERSONALIZED; MEDICINE, BY SERVICES, THROUGH 2014 ($ MILLIONS); TABLE 90 EUROPEAN MARKET FORECAST FOR PERSONALIZED; MEDICINE, BY PRODUCTS, THROUGH 2014 ($ MILLIONS); TABLE 91 EUROPEAN MARKET FORECAST FOR PERSONALIZED; MEDICINE, BY APPLICATIONS, THROUGH 2014 ($ MILLIONS); TABLE 92 MAJOR ACTIVITIES IN EUROPEAN MARKET; TABLE 93 ASIA PACIFIC MARKET FORECAST FOR PERSONALIZED; MEDICINE, BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS); TABLE 94 ASIA PACIFIC MARKET FORECAST FOR PERSONALIZED; MEDICINE, BY APPLICATIONS, THROUGH 2014 ($ MILLIONS); TABLE 95 IMPORTANT ACTIVITIES IN ASIA PACIFIC MARKET; TABLE 96 NEW PRODUCT LAUNCHES IN ASIA PACIFIC MARKET; TABLE 97 PRODUCT PORTFOLIO OF ABBOTT; TABLE 98 PRODUCT PORTFOLIO OF AFFYMETRIX (MICROARRAYS); TABLE 99 PRODUCT PORTFOLIO OF AFFYMETRIX; (REAGENTS & ASSAYS); TABLE 100 PRODUCT PORTFOLIO OF AGENDIA BV; TABLE 101 PRODUCT PORTFOLIO OF ASURAGEN; TABLE 102 PRODUCT PORTFOLIO OF BAYER HEALTHCARE; TABLE 103 PRODUCT PORTFOLIO OF BIOGEN (IDEC); TABLE 104 PRODUCT PORTFOLIO OF BRISTOL-MYERS SQUIBB; TABLE 105 PRODUCT PORTFOLIO OF CELERA DIAGNOSTICS; TABLE 106 NEW PRODUCT DEVELOPMENT OF CELERA; DIAGNOSTICS; TABLE 107 PRODUCT PORTFOLIO OF CEPHEID; TABLE 108 PRODUCT PORTFOLIO OF CLINICAL DATA; TABLE 109 PRODUCT PORTFOLIO OF CURAGEN CORP; TABLE 110 PRODUCT PORTFOLIO OF DAKO DENMARK A/S; TABLE 111 PRODUCT PORTFOLIO OF DECODE GENETICS; TABLE 112 NEW PRODUCT DEVELOPMENT OF DECODE GENETICS; TABLE 113 PRODUCT PORTFOLIO OF DNA DIRECT, INC; TABLE 114 PRODUCT PORTFOLIO OF DXS LIMITED; TABLE 115 PRODUCT PORTFOLIO OF EXACT SCIENCES CORP.; TABLE 116 PRODUCT PORTFOLIO OF EXAGEN DIAGNOSTICS; TABLE 117 PRODUCT PORTFOLIO OF GENE LOGIC; TABLE 118 PRODUCT PORTFOLIO OF GENELEX CORP; TABLE 119 PRODUCT PORTFOLIO OF GENENTECH, INC.; TABLE 120 PRODUCT PORTFOLIO OF GENOMIC HEALTH INC; TABLE 121 PRODUCT PORTFOLIO OF GEN-PROBE; TABLE 122 NEW PRODUCT DEVELOPMENT OF GEN-PROBE; TABLE 123 PRODUCT PORTFOLIO OF GENTA; TABLE 124 NEW PRODUCT DEVELOPMENT OF GENTA; TABLE 125 PRODUCT PORTFOLIO OF GLAXOSMITHKLINE; TABLE 126 PRODUCT PORTFOLIO OF ILLUMINA; TABLE 127 PRODUCT PORTFOLIO OF LUMINEX CORP; TABLE 128 PRODUCT PORTFOLIO OF MILLENNIUM; TABLE 129 PRODUCT PORTFOLIO OF MONOGRAM BIOSCIENCES; TABLE 130 PRODUCT PORTFOLIOS OF MYRIAD GENETICS; TABLE 131 NEW PRODUCT DEVELOPMENT OF MYRIAD GENETICS; TABLE 132 PRODUCT PORTFOLIO OF NANOGEN; TABLE 133 PRODUCT PORTFOLIO OF NOVARTIS; TABLE 134 PRODUCT PORTFOLIO OF WYETH; TABLE 135 PRODUCT PORTFOLIO OF PROMEGA; TABLE 136 PRODUCT PORTFOLIO OF QIAGEN; TABLE 137 PRODUCT PORTFOLIO OF ROCHE; DIAGNOSTICS; TABLE 138 PRODUCT PORTFOLIO OF SIEMENS HEALTHCARE; DIAGNOSTICS; TABLE 139 PRODUCT PORTFOLIO OF TARGET DISCOVERY; TABLE 140 PRODUCT PORTFOLIO OF VENTANA MEDICALSYSTEMS,; INC; TABLE 141 PRODUCT PORTFOLIO OF WYETH; TABLE 142 PATENTS ISSUED IN THE UNITED STATES; TABLE 143 PATENTS ISSUED IN EUROPE
LIST OF FIGURES: SUMMARY FIGURE GLOBAL MARKET FORECAST FOR; PERSONALIZED MEDICINE, BY TECHNOLOGY, 2007-2014; ($ MILLIONS); FIGURE 1 PERSONALIZED MEDICINE VS CONVENTIONAL; TREATMENTS; FIGURE 2 FOCUS OF PERSONALIZED MEDICINE; FIGURE 3 PERSONALIZED MEDICINE VS BLOCKBUSTER DRUGS; FIGURE 4 MAJOR MARKET TRENDS IN PERSONALIZED MEDICINE; FIGURE 5 PARTICIPATION OF STAKEHOLDERS; FIGURE 6 MARKET STRUCTURE FOR PERSONALIZED MEDICINE; FIGURE 7 GLOBAL MARKET FORECAST FOR PERSONALIZED; MEDICINE, BY TECHNOLOGY, 2007-2014 ($ MILLIONS); FIGURE 8 GLOBAL MARKETS FOR PERSONALIZED MEDICINE, 2009; (%); FIGURE 9 NUMBER OF PATENTS ISSUED, JAN. 2004- APR. 2009; FIGURE 10 POSITIONING VARIOUS TECHNOLOGIES IN THE MARKET; FOR PERSONALIZED MEDICINE; FIGURE 11 SHARE OF PATENTS BY TECHNOLOGY (%); FIGURE 12 PRODUCT LIFE CYCLE FOR PERSONALIZED MEDICINE; PRODUCTS; FIGURE 13 GLOBAL MARKET FORECAST FOR PERSONALIZED; MEDICINE, BY APPLICATION, THROUGH 2014 ($ BILLIONS); FIGURE 14 NUMBER OF PATENTS ISSUED, BY GEOGRAPHY, JAN; 2004 - APR 2009); FIGURE 15 EUROPEAN MARKETS FOR PERSONALIZED MEDICINE,; 2009 (%); FIGURE 16 ASIA PACIFIC MARKET FORECAST FOR PERSONALIZED; MEDICINE, BY PRODUCTS & SERVICES, THROUGH 2014; ($ BILLIONS)

More Global Personalized Medicine Reports

Personalized Medicine: Companies, Trends and World Market by Takeda Pacific
This broad, high-level report analyzes the expanding Personalized Medicine market. This world market includes important core medical product areas that will continue to have ...

Personalized Medicine Market Worldwide (2010 - 2015) - By Segments, Technologies, Opportunities, Challenges & Future Forecast by Renub Research
Renub Research report titled “Personalized Medicine Market Worldwide (2010 - 2015) - By Segments, Technologies, Opportunities, Challenges & Future Forecast” analysis the global personalized medicine. ...

See all reports like this >>

Personalized Medicine: Technologies and the Global Market

Share this report

Other tasks

Research Assistance

Related Markets

Personalized Medicine Reports

Free Alert Me service